Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Hepatitis C virus is not cleared after primary infection in 50-85% of subjects exposed to hepatitis C virus. Anti-viral treatment during the early phase of infection significantly enhances the likelihood of a sustained clearance of hepatitis C virus. Although, a variety of autoimmune-related side effects have been observed during interferon therapy for chronic hepatitis, immuno-mediated adverse reactions have not been reported during treatment of acute hepatitis C. We describe the case of a patient who developed acute hepatitis C virus infection and, while receiving pegylated interferon alpha-2b monotherapy, developed a severe polymyositis. This case illustrates the potential risk of autoimmunity by interferon, also for acute hepatitis, and underlines the importance of a prompt diagnosis and a rapid discontinuation of interferon treatment for an improvement of clinical outcomes. © 2005 Editrice Gastroenterologica Italiana S.r.l.
Original languageEnglish
Pages (from-to)882-885
Number of pages4
JournalDigestive and Liver Disease
Volume37
Publication statusPublished - 2005

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b'. Together they form a unique fingerprint.

Cite this